REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 20, 2021, is by and among Allarity Therapeutics, Inc., a Delaware corporation with offices located at 210 Broadway, Ste 201, Cambridge, MA 02139 (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • New York
This Exclusive License Agreement (this “Agreement”) is entered into as of July 6, 2017 (the “Effective Date”), between Oncology Venture, ApS, a company organized and existing under the laws of Denmark, whose principal place of business is located at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”)
LICENSE AGREEMENT between NOVARTIS PHARMA AG and ONCOLOGY VENTURE ApSLicense Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • New York
This LICENSE AGREEMENT (“License Agreement”) is made as of the 6. day of April, 2018 (“Effective Date”), by and between Novartis Pharma AG, a company organized under the laws of Switzerland and located at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”), and Oncology Venture ApS, a company organized under the laws of Denmark, with headquarters at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”). Novartis and OV are each referred to individually as a “Party” and together as the “Parties.”
ONCOLOGY VENTURE ApS and R-PHARM US OPERATING, LLC DEVELOPMENT, OPTION AND LICENSE AGREEMENTDevelopment, Option and License Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • New York
The first communication from Partner to R-Pharm US should be communicated in writing by email (and confirmed by fax) to the contact point of the Pharmacovigilance contact person of R-Pharm US.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 20th, 2021 • Allarity Therapeutics, Inc.
This Exclusive License Agreement (this “Agreement”) is entered into as of June 25, 2020 (the “Execution Date”), between Oncology Venture A/S, a company organized and existing under the laws of Denmark, whose principal place of business is located at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”)
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 20, 2021, is by and among Allarity Therapeutics, Inc., a Delaware corporation with offices located at 210 Broadway, Ste 201, Cambridge, MA 02139 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • Delaware
This Asset Purchase Agreement (this “Agreement”), dated as of July 23, 2021 (the “Effective Date”), is entered into between Allarity Therapeutics A/S, formerly known as Oncology Venture ApS, (Company Registration no. 34 62 35 62), a Danish corporation (“Allarity”) and Lantern Pharma Inc., a Delaware corporation (“Lantern”). Allarity and Lantern are each referred to herein individually as a “Party” and collectively as the “Parties”.
ContractLicense Agreement • August 20th, 2021 • Allarity Therapeutics, Inc.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 20th, 2021 • Allarity Therapeutics, Inc. • New York
This Exclusive License Agreement (this “Agreement”) is entered into as of March 27, 2017 (the “Effective Date”), between Oncology Venture, ApS, a company organized and existing under the laws of Denmark, whose principal place of business is located at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“OV”)
